H.C. Wainwright initiates coverage on Mirati Therapeutics (NASDAQ: MRTX) with a Buy rating and a price target of $12.00.Analyst Shaunak ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE